Screener
Haemonetics HAE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | June 27, 2026 | March 28, 2026 |
|---|---|---|
| Deferred tax liability | 38,691 | 38,048 |
| Other long-term liabilities | 57,171 | 59,393 |
| Stockholders’ equity: | ||
| Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 45,471,313 shares as of June 27, 2026 and 45,252,667 shares as of March 28, 2026 | 455 | 453 |
| Additional paid-in capital | 566,759 | 554,137 |
| Retained earnings | 311,516 | 279,344 |
| Accumulated other comprehensive loss | (41,629) | (37,614) |
| Total stockholders’ equity | 837,101 | 796,320 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's common stock?
- Haemonetics (HAE) reported common stock of 150M in Q2 2026.
- How has Haemonetics's common stock changed year-over-year?
- Haemonetics's common stock decreased by 0.0% year-over-year, from 150M to 150M.
- What is the long-term trend for Haemonetics's common stock?
- Over 5 years (2021 to 2026), Haemonetics's common stock has grown at a 211.8% compound annual growth rate (CAGR), from 509K to 150M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Haemonetics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude